Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06096675 · ClinicalTrials.gov registry record · NA
CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study
A NA study of Cardiac Amyloidosis, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06096675: Recruiting NA study of Cardiac Amyloidosis, sponsored by Wake Forest University Health Sciences.
NCT06096675 is a NA study of Cardiac Amyloidosis that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 50 participants, below the 948-participant average among 8 other Cardiac Amyloidosis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06096675, a NA study of Cardiac Amyloidosis, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Exercise training in patients with heart failure and preserved ejection fraction (HFpEF) has been associated with an improvement in cardiorespiratory fitness and quality of life.
Primary Outcome
Feasibility of cardiac rehab as measured by number of participants that complete at least 75% of prescribed cardiac rehab sessions.
Conditions Studied
Interventions
- BEHAVIORAL • Cardiac Rehabilitation
Study Locations (1)
North Carolina
- Sanger Heart and Vascular Institute - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-01-22 |
| Est. Completion | 2027-06 |
| Phase | NA |
What NCT06096675 shows while recruiting
NCT06096675 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 948-participant average among 8 other Cardiac Amyloidosis trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Cardiac Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which • Cardiac Rehabilitation is the first listed.
NCT06096675 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06096675 about?
NCT06096675 is a clinical study titled "CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study". Exercise training in patients with heart failure and preserved ejection fraction (HFpEF) has been associated with an improvement in cardiorespiratory fitness and quality of life.
What is the current status of trial NCT06096675?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2024-01-22. Estimated completion is 2027-06.
What conditions does trial NCT06096675 study?
This clinical trial studies the following conditions: Cardiac Amyloidosis.
What interventions are being tested in trial NCT06096675?
The interventions under investigation include: • Cardiac Rehabilitation (BEHAVIORAL).
Who is sponsoring clinical trial NCT06096675?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06096675 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiac Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06096675's enrollment target sits among peer trials
50 8th of 8 higher than 1 of 8 other Cardiac Amyloidosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiac Amyloidosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cardiovascular Multimodality Imaging Study
RECRUITING
-
Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)
RECRUITING
-
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
RECRUITING
-
US Benchmarking Clinical Study
RECRUITING
-
Molecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis
RECRUITING · Phase 3
-
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI